Ocular Therapeutix

Yahoo Finance • 2 hours ago

Ocular Therapeutix prices $475M stock offering

* Ocular Therapeutix (NASDAQ:OCUL [https://seekingalpha.com/symbol/OCUL]) has priced an offering of 37.9M shares at $12.53 each, aiming to raise gross proceeds of around $475.0 million. * The offering is expected to close on or about O... Full story

Yahoo Finance • 3 hours ago

Ocular Therapeutix™ Announces Pricing of Underwritten Offering of Common Stock

BEDFORD, Mass., Sept. 30, 2025 (GLOBE NEWSWIRE) -- Ocular Therapeutix, Inc. (Nasdaq: OCUL) (“Ocular”, the “Company”), an integrated biopharmaceutical company committed to redefining the retina experience, today announced the pricing of a... Full story

Yahoo Finance • 3 hours ago

Ocular Therapeutix™ Investor Day to Highlight Exceptional AXPAXLI™ Progress Across SOL Program and Detail Registrational Trial Plans to Pursue a Diabetic Retinopathy Label with a Novel Primary Endpoint

SOL-1 superiority trial continues to demonstrate outstanding patient retention and protocol adherence, with no new or unexpected safety signals observed to date; topline data on track for 1Q 2026 Event to detail how robust SOL-R patient s... Full story

Yahoo Finance • 24 days ago

Key deals this week: Ocular Therapeutix, CoreWeave, Air Lease, Cadence and more

Here's a list of key deals reported across sectors this week: Ocular Therapeutix (NASDAQ:OCUL [https://seekingalpha.com/symbol/OCUL]) rose 6% amid takeover [https://seekingalpha.com/news/4492779-ocular-therapeutix-gains-amid-takeover-spec... Full story

Yahoo Finance • 2 months ago

Ocular gets FDA agreement for registrational trial of Axpaxl

[Eye Exam] Geber86/E+ via Getty Images * Ocular Therapeutix (NASDAQ:OCUL [https://seekingalpha.com/symbol/OCUL]) said it got written agreement regarding a registrational trial design from the FDA for the trial of Axpaxl in non-prolifera... Full story

Yahoo Finance • 2 months ago

Ocular Therapeutix secures FDA agreement for diabetic retinopathy trial

BEDFORD, Mass. - Ocular Therapeutix, Inc. (NASDAQ:OCUL), currently valued at $2.19 billion and trading near its 52-week high of $12.65, announced Tuesday it has received a Special Protocol Assessment (SPA) agreement from the U.S. Food and... Full story

Yahoo Finance • 2 months ago

OCULAR THERAPEUTIX INC (NASDAQ:OCUL) Reports Mixed Q2 2025 Earnings Amid Clinical Progress

OCULAR THERAPEUTIX INC (NASDAQ:OCUL [https://www.chartmill.com/stock/quote/OCUL/profile]) reported its second-quarter 2025 financial results, delivering mixed performance relative to analyst expectations. The company's revenue and earnings... Full story

Yahoo Finance • 2 months ago

Ocular Therapeutix stock maintains Strong Buy rating at Raymond James

Investing.com - Raymond James has reiterated its Strong Buy rating and $19.00 price target on Ocular Therapeutix (NASDAQ:OCUL), currently trading at $12.08, following the company’s presentations at the American Society of Retina Specialist... Full story

Yahoo Finance • 2 months ago

Ocular Therapeutix Q2 2025 Earnings Preview

* Ocular Therapeutix (NASDAQ:OCUL [https://seekingalpha.com/symbol/OCUL]) is scheduled to announce Q2 earnings results on Tuesday, August 5th, before market open. * The consensus EPS Estimate is -$0.35 [https://seekingalpha.com/symbol/... Full story

Yahoo Finance • 2 years ago

Ocular Therapeutix™ Announces Proposed Public Offering of Common Stock

Ocular Therapeutix, Inc. BEDFORD, Mass., Dec. 13, 2023 (GLOBE NEWSWIRE) -- Ocular Therapeutix™, Inc. (Nasdaq: OCUL) (the “Company”), a biopharmaceutical company focused on the formulation, development, and commercialization of innovative... Full story

Yahoo Finance • 2 years ago

Ocular Therapeutix™ to Present at Three Upcoming Investor Conferences

BEDFORD, Mass., Nov. 08, 2023 (GLOBE NEWSWIRE) -- Ocular Therapeutix, Inc. (NASDAQ:OCUL) a biopharmaceutical company focused on the formulation, development, and commercialization of innovative therapies for diseases and conditions of th... Full story

Yahoo Finance • 2 years ago

Ocular Therapeutix™ Provides Third Quarter 2023 Financial Results and Corporate Update

FDA Agrees to Overall Design of the First Pivotal Trial for AXPAXLI in Wet AMD under a Special Protocol Assessment; Expect First Subject Dosed by Year-End Top-line Data from U.S.-based HELIOS Trial Evaluating AXPAXLI for Treatment of Non-... Full story

Yahoo Finance • 2 years ago

Ocular Therapeutix™ Receives FDA Agreement Under Special Protocol Assessment (SPA) for its First Pivotal Clinical Trial of OTX-TKI in Wet AMD

The first subject expected to be dosed by year-end Company announces OTX-TKI trade name AXPAXLI BEDFORD, Mass., Nov. 01, 2023 (GLOBE NEWSWIRE) --  Ocular Therapeutix, Inc. (NASDAQ:OCUL), a biopharmaceutical company focused on the formu... Full story

Yahoo Finance • 2 years ago

Ocular Therapeutix™ To Report Third Quarter 2023 Financial Results

BEDFORD, Mass., Oct. 24, 2023 (GLOBE NEWSWIRE) -- Ocular Therapeutix, Inc. (NASDAQ:OCUL), a biopharmaceutical company focused on the formulation, development, and commercialization of innovative therapies for diseases and conditions of t... Full story

Yahoo Finance • 2 years ago

Ocular Therapeutix™ Announces Initiation of its First Pivotal Clinical Trial of OTX-TKI in Wet AMD

BEDFORD, Mass., Oct. 03, 2023 (GLOBE NEWSWIRE) -- Ocular Therapeutix, Inc. (NASDAQ: OCUL), a biopharmaceutical company focused on the formulation, development and commercialization of innovative therapies for diseases and conditions of t... Full story

Yahoo Finance • 2 years ago

10 Best Rising Penny Stocks to Buy

In this article, we will take a look at the 10 best rising penny stocks to buy. To see more such companies, go directly to 5 Best Rising Penny Stocks to Buy. Amid too much volatility everyone seems to avoid small companies that are workin... Full story

Yahoo Finance • 2 years ago

Ocular Therapeutix™ Announces Appointment of New Board Member

BEDFORD, Mass., July 12, 2023 (GLOBE NEWSWIRE) -- Ocular Therapeutix, Inc. (NASDAQ: OCUL), a biopharmaceutical company focused on the formulation, development, and commercialization of innovative therapies for diseases and conditions of... Full story

Yahoo Finance • 2 years ago

Ocular Therapeutix™ Announces 12-Month Topline Data from Ongoing U.S.-Based Phase 1 Clinical Trial Evaluating OTX-TKI for Treatment of Wet AMD

OTX-TKI maintained vision and CSFT comparable to aflibercept every eight weeks, with 89% reduction in treatment burden over a 12-month period OTX-TKI demonstrated no drug-related ocular or systemic serious adverse events in the trial thro... Full story

Yahoo Finance • 2 years ago

3 Low-Priced Stocks -- And How I'm Trading Them

Small-cap stocks are lagging with a decline of about 1%, and there is minimal, speculative action. In a healthier market environment, I would be focused on buying stocks that are showing relative strength, and I would chase them higher, bu... Full story

Yahoo Finance • 2 years ago

Ocular Therapeutix™ To Present Data at the 2023 American Society of Cataract and Refractive Surgery (ASCRS) Annual Meeting

BEDFORD, Mass., April 28, 2023 (GLOBE NEWSWIRE) -- Ocular Therapeutix, Inc. (NASDAQ:OCUL), a biopharmaceutical company focused on the formulation, development, and commercialization of innovative therapies for diseases and conditions of... Full story